Neurology
We are applying our deep expertise in radiopharmaceutical science to shed light on neurological disorders, researching potential next-generation radiodiagnostics with the hope of earlier detection and better patient outcomes.
Decades of unmet need
Alzheimer’s disease and other forms of dementia remain a significant challenge in the neurological disease space, with over 55 million people worldwide directly affected.1 The emotional and financial burden on families is immense, with a lack of tools to help manage this diagnosis and caregivers providing an average of five hours of care and supervision per day.2
Someone in the world develops dementia every 3 seconds1
10M new cases of dementia each year worldwide1
Read Carolyn’s story of compassion and resilience as she supports her husband, Dave, through his Alzheimer’s journey.
Targeting hallmarks of Alzheimer’s disease
With our legacy in precision diagnostics, Lantheus is advancing a suite of radiodiagnostic tools to help unlock the mysteries of neurological disorders like Alzheimer’s disease. These targeted radiotracers, in conjunction with imaging modalities like positron emission tomography (PET), may help identify disease biomarkers with precision and clarity, potentially allowing for earlier detection and intervention.
Our science focuses on tau tangles and beta-amyloid plaques: two biomarkers that are hallmarks of Alzheimer’s disease.3
Tau
Tau proteins help maintain the structure and function of neurons by stabilizing their internal transport system. In Alzheimer’s disease, these proteins become abnormal and form tangles inside neurons. This disrupts communication and leads to cell death, making tau tangles an indicator of disease progression.4
Beta amyloid
Beta amyloid is a protein fragment that accumulates between neurons in Alzheimer’s disease, forming plaques. These plaques disrupt communication between neurons and are strongly linked to cognitive decline. Beta-amyloid plaques are a key indicator of Alzheimer’s disease.4
Why Lantheus fights
to find disease
Scientists believe tau tangles and beta-amyloid plaques begin forming one to two decades before signs or symptoms of Alzheimer’s disease appear.5 With this knowledge in mind, Lantheus is driven to advance our portfolio of next-generation tools that carry the vision of improved diagnostic performance. We believe this could lead to earlier detection and, for patients, a sense of hope that tomorrow may be brighter.
REFERENCES
1. Dementia Statistics. Alzheimer’s Disease International. Accessed September 10, 2025. https://www.alzint.org/about/dementia-facts-figures/dementia-statistics/ 2. Dementia. World Health Organization. Published March 31, 2025. Accessed September 10, 2025. https://www.who.int/news-room/fact-sheets/detail/dementia 3. Researchers Study Effectiveness of Tau Biomarkers in Alzheimer’s Blood Test Among Diverse Participants. National Institute on Aging. Published May 20, 2021. Accessed September 10, 2025. https://www.nia.nih.gov/news/researchers-study-effectiveness-tau-biomarkers-alzheimers-blood-test-among-diverse 4. What Happens to the Brain in Alzheimer’s Disease? National Institute on Aging. Published January 19, 2024. Accessed May 21, 2025. https://www.nia.nih.gov/health/alzheimers-causes-and-risk-factors/what-happens-brain-alzheimers-disease 5. Alzheimer’s Disease Fact Sheet. National Institute on Aging. Published April 5, 2023. Accessed May 21, 2025. https://www.nia.nih.gov/health/alzheimers-and-dementia/alzheimers-disease-fact-sheet
